Table 4. 3-year-and 5-year overall survival according to the 8th edition American Joint Committee on Cancer N category and ypNr category.
| ypN stages | ypNr stage | |||
|---|---|---|---|---|
| ypNr0 (n=61) (91.8%/91.8%) | ypNr1 (n=92) (77.2%/63.4%) | ypNr2 (n=70) (47.1%/31.8%) | ypNr3 (n=42) (28.6%/7.8%) | |
| ypN0 (n=84) (86.9%/84.2%)* | n=61 (91.8%/91.8%) | n=23 (73.9%/65.2%) | - | - |
| ypN1 (n=58) (74.1%/62.4%) | - | n=51 (76.5%/65.1%) | n=7 (57.1%/42.9%) | - |
| ypN2 (n=59) (62.7%/42.1%) | - | n=17 (76.5%/60.5%) | n=40 (55%/36.3%) | n=2 (50%/0%) |
| ypN3 (n=64) (29.7%/12.8%) | - | n=1 (100%/0%)† | n=23 (30.4%/20.3%) | n=40 (27.5%/8.3%) |
*The 3-year overall survival/5-year overall survival; †Only 1 patient with ypN3 (7/86) was categorized as ypNr1, with an overall survival time of 55 months.